Kate Bingham joined SV Health in 1991.
Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.
Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Affinium, Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, MedNova, Micromet, Oncoethix, PowderMed, RespiVert and Vantia and current investments including Atopix, Autifony, Bicycle, Convergence, Kalvista, Karus, Pulmocide, TopiVert and VHSquared.
Prior to joining SV Health, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.
- +44 (0) 20 7421 7071